Trial · NCT03904693
Participant flow54
How many started, completed or left each group, period by period.
41 to 54 of 54
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| OL Treatment Period (Week 17 to Week189) | STARTED | OL: Treatment-naive and Prior PDE-5i Strata: M/T FDC | 43 | |
| OL Treatment Period (Week 17 to Week189) | STARTED | OL: Treatment-naive and Prior ERA/ PDE-5i Strata: M/T FDC | 91 | |
| OL Treatment Period (Week 17 to Week189) | COMPLETED | DB: Treatment-naive and Prior ERA Strata: Macitentan Monotherapy 10 Milligrams (mg) | 0 | |
| OL Treatment Period (Week 17 to Week189) | COMPLETED | DB: Treatment-naive and Prior PDE-5i Strata: Tadalafil Monotherapy 20 mg (2 Tablets*20 mg) | 0 | |
| OL Treatment Period (Week 17 to Week189) | COMPLETED | DB: Treatment-naive and Prior ERA/ PDE-5i Strata: M/T FDC | 0 | |
| OL Treatment Period (Week 17 to Week189) | COMPLETED | OL: Treatment-naive and Prior ERA Strata: M/T FDC | 30 | |
| OL Treatment Period (Week 17 to Week189) | COMPLETED | OL: Treatment-naive and Prior PDE-5i Strata: M/T FDC | 38 | |
| OL Treatment Period (Week 17 to Week189) | COMPLETED | OL: Treatment-naive and Prior ERA/ PDE-5i Strata: M/T FDC | 76 | |
| OL Treatment Period (Week 17 to Week189) | NOT COMPLETED | DB: Treatment-naive and Prior ERA Strata: Macitentan Monotherapy 10 Milligrams (mg) | 0 | |
| OL Treatment Period (Week 17 to Week189) | NOT COMPLETED | DB: Treatment-naive and Prior PDE-5i Strata: Tadalafil Monotherapy 20 mg (2 Tablets*20 mg) | 0 | |
| OL Treatment Period (Week 17 to Week189) | NOT COMPLETED | DB: Treatment-naive and Prior ERA/ PDE-5i Strata: M/T FDC | 0 | |
| OL Treatment Period (Week 17 to Week189) | NOT COMPLETED | OL: Treatment-naive and Prior ERA Strata: M/T FDC | 5 | |
| OL Treatment Period (Week 17 to Week189) | NOT COMPLETED | OL: Treatment-naive and Prior PDE-5i Strata: M/T FDC | 5 | |
| OL Treatment Period (Week 17 to Week189) | NOT COMPLETED | OL: Treatment-naive and Prior ERA/ PDE-5i Strata: M/T FDC | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03904693/flow?page=3